Jaguar Health Past Earnings Performance
Past criteria checks 0/6
Jaguar Healthhan disminuido a un ritmo medio anual de -4.8%, mientras que en la industria Pharmaceuticals los ingresos han sido de growing a 8.5% anuales. Los ingresos han sido growing a una tasa media anual de 16.9%.
Key information
-4.0%
Earnings growth rate
100.6%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 15.6% |
Return on equity | -855.6% |
Net Margin | -423.1% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth
Mar 29Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%
Jan 22Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump
Jun 10Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt
Jan 23Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment
Oct 17Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront
Aug 25Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule
Aug 19Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea
Aug 09Jaguar stock rises on license deal with SynWorld for Canalevia in China
Jun 29Jaguar Health CEO Lisa Conte - From Rainforest To Laboratory
Mar 07Jaguar Health shares jumps 13% after pricing $15M direct offering
Jan 13Jaguar Health plans for conditional marketing application in Europe for Crofelemer, initially for Long-Hauler COVID-19 patients
Jan 11Jaguar Health leaps higher in new year
Jan 05Jaguar Health inks second Mytesi royalties agreement for $6M
Dec 23Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?
Dec 02Jaguar Health's crofelemer development nears SPAC funding in Europe, shares +61%
Nov 30Jaguar Health EPS misses by $0.10, misses on revenue
Nov 16Jaguar Health receives positive Nasdaq listing determination
Oct 29Revenue & Expenses BreakdownBeta
How Jaguar Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 10 | -41 | 23 | 19 |
30 Sep 23 | 11 | -40 | 22 | 19 |
30 Jun 23 | 11 | -44 | 24 | 19 |
31 Mar 23 | 11 | -42 | 24 | 17 |
31 Dec 22 | 12 | -47 | 27 | 18 |
30 Sep 22 | 11 | -54 | 29 | 19 |
30 Jun 22 | 8 | -54 | 29 | 16 |
31 Mar 22 | 6 | -59 | 29 | 18 |
31 Dec 21 | 4 | -53 | 26 | 15 |
30 Sep 21 | 5 | -50 | 23 | 12 |
30 Jun 21 | 7 | -46 | 23 | 10 |
31 Mar 21 | 10 | -42 | 21 | 7 |
31 Dec 20 | 9 | -39 | 20 | 6 |
30 Sep 20 | 8 | -35 | 21 | 6 |
30 Jun 20 | 7 | -39 | 20 | 6 |
31 Mar 20 | 5 | -45 | 20 | 6 |
31 Dec 19 | 6 | -45 | 20 | 6 |
30 Sep 19 | 6 | -48 | 21 | 4 |
30 Jun 19 | 6 | -43 | 22 | 3 |
31 Mar 19 | 5 | -34 | 22 | 1 |
31 Dec 18 | 4 | -32 | 22 | 0 |
30 Sep 18 | 4 | -41 | 21 | 0 |
30 Jun 18 | 4 | -30 | 16 | 0 |
31 Mar 18 | 4 | -24 | 13 | 0 |
31 Dec 17 | 4 | -22 | 11 | 0 |
30 Sep 17 | 3 | -5 | 8 | 0 |
30 Jun 17 | 2 | -14 | 9 | 0 |
31 Mar 17 | 1 | -17 | 9 | 0 |
31 Dec 16 | 0 | -15 | 6 | 0 |
31 Dec 15 | 0 | 5 | 3 | 2 |
Beneficios de calidad: JAGX actualmente no es rentable.
Creciente margen de beneficios: JAGX actualmente no es rentable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Tendencia de beneficios: JAGX no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 4.8% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de JAGX en el último año con su media de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: JAGX no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Pharmaceuticals (-17.3%).
Return on Equity
Alto ROE: JAGX tiene un Rendimiento de los fondos propios negativo (-2883.05%), ya que actualmente no es rentable.